478375-37-0

Basic information

• Product Name: 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester
• Synonyms: 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester;methyl 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
• CAS NO: 478375-37-0
• Molecular Formula: C₁₅H₂₁BO₅
• Molecular Weight: 292.13524
• Mol File: 478375-37-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester(478375-37-0)
• EPA Substance Registry System: 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester(478375-37-0)

Safety Data

• Hazardous Substances Data: 478375-37-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester is used as a reagent for Suzuki-Miyaura coupling reactions, which are crucial for the formation of carbon-carbon bonds in organic molecules. This application is vital for constructing complex organic structures and expanding the scope of synthetic chemistry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester is utilized for the development of pharmaceuticals. Its ability to modify and fine-tune the properties of organic molecules makes it a valuable component in the design and synthesis of new drugs with improved efficacy and selectivity.
Used in Agrochemical Development:
2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester also has potential applications in the agrochemical industry. It can be employed to create new agrochemicals or improve existing ones, contributing to more effective and targeted pest control solutions in agriculture.
Used in Materials Science:
In the realm of materials science, 2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester is used for the synthesis of advanced polymers and functional materials. Its incorporation into these materials can lead to the development of new properties and applications, such as improved mechanical strength, thermal stability, or specific interactions with other molecules.

Upstream product

• 2476-35-9 5-bromo-2-methoxybenzoic acid 
• 73183-34-3 bis(pinacol)diborane 
• 509074-76-4 methyl 2-methoxy-5-(toluene-p-sulfonyloxy)benzoate 
• 40757-09-3 methyl 2-methoxy-5-iodobenzoate 
• 89-55-4 5-bromosalicyclic acid 
• 7120-41-4 methyl 5-bromo-2-methoxybenzoate 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 

Downstream Products

• 1380656-61-0 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl)-2-methoxybenzoic acid 
• 1380656-62-1 2-(4-fluorophenyl)-5-(4-methoxy-3-((3-(pyrimidin-2-yl)oxetan-3-yl)carbamoyl)phenyl)-N-methyl-6-nitrobenzofuran-3-carboxamide 
• 1380656-63-2 6-amino-2-(4-fluorophenyl)-5-(4-methoxy-3-((3-(pyrimidin-2-yl)-oxetan-3-yl)carbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide 
• 1380656-64-3 6-(ethylamino)-2-(4-fluorophenyl)-N-methyl-5-(4-methoxy-3-(3-(pyrimidin-2-yl)oxetan-3-ylcarbamoyl)phenyl)benzofuran-3-carboxamide 
• 1380656-60-9 methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl)-2-methoxybenzoate 
• 13987-45-6 4,4’-dihydroxy-(1,1’-biphenyl)-3,3’-dicarboxylic acid 
• 1623061-09-5 4,4′′-dihydroxy-[1,1′:4′,1′′-terphenyl]-3,3′′-dicarboxylic acid 
• 1449332-95-9 methyl 5-(2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)-6-nitrobenzofuran-5-yl)-2-methoxybenzoate 

Relevant articles and documents

Molecular Insight into Fluorocarbon Adsorption in Pore Expanded Metal-Organic Framework Analogs

The rapid growth in the global energy demand for space cooling requires the development of more efficient environmental chillers for which adsorption-based cooling systems can be utilized. Here, in this contribution, we explore sorbents for chiller use via a pore-engineering concept to construct analogs of the 1-dimensional pore metal-organic framework MOF-74 by using elongated organic linkers and stereochemistry control. The prepared pore-engineered MOFs show remarkable equilibrium adsorption of the selected fluorocarbon refrigerant that is translated to a modeled adsorption-based refrigeration cycle. To probe molecular level interactions at the origin of these unique adsorption properties for this series of Ni-MOFs, we combined in situ synchrotron X-ray powder diffraction, neutron powder diffraction, X-ray absorption spectroscopy, calorimetry, Fourier transform infrared techniques, and molecular simulations. Our results reveal the coordination of fluorine (of CH2F in R134a) to the nickel(II) open metal centers at low pressures for each Ni-MOF analog and provide insight into the pore filling mechanism for the full range of the adsorption isotherms. The newly designed Ni-TPM demonstrates exceptional R134a adsorption uptake compared to its parent microporous Ni-MOF-74 due to larger engineered pore size/volume. The application of this adsorption performance toward established chiller conditions yields a working capacity increase for Ni-TPM of about 400% from that of Ni-MOF-74, which combined with kinetics directly correlates to both a higher coefficient of performance and a higher average cooling capacity generated in a modeled chiller.

PI4KIIIBETA INHIBITORS

The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral inf

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

Room Temperature Ni0/PCy3-Catalyzed Coupling Reactions of Aryl Arenesulfonates with Bis(pinacolato)diboron

Room temperature Ni0/PCy3-catalyzed cross-coupling reactions of aryl arenesulfonates with bis(pinacolato)diboron are described. The Ni0/PCy3 catalysts, generated from Ni(COD)2 and PCy3, or air-stable 4-MeOC6H4NiII(PCy3)2OTs, were efficient catalyst systems for the Miyaura borylation reactions of a variety of aryl arenesulfonates with bis(pinacolato)diboron. The mild reaction condition, the easy availability of the catalysts and good yields make these reactions potentially useful in organic synthesis (Cy = cyclohexyl, COD = cyclooctadiene, OTs = tosyl).

NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF

Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.

Pore Environment Effects on Catalytic Cyclohexane Oxidation in Expanded Fe2(dobdc) Analogues

Metal-organic frameworks are a new class of heterogeneous catalysts in which molecular-level control over both the immediate and long-range chemical environment surrounding a catalytic center can be readily achieved. Here, the oxidation of cyclohexane to

BENZOFURANE DERIVATIVES FOR THE TREATMENT OF HEPATITITS C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and maybe useful in treating those infected with HCV.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer

Investigation of the asymmetric Birch reduction-alkylation of a chiral 5-arylbenzamide containing a carbamate group

The synthesis and asymmetric Birch reduction-alkylation of chiral benzamide 17 are described. Birch reductive alkylation of benzamide 17 was optimized to give the corresponding cyclohexa-1,4-diene products in 66-78% isolated yield and with high diastereoselectivity (dr: >98:2). The effects of performing the reduction in the presence and in the absence of tert-butyl alcohol are discussed.